X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (553) 553
Book Review (167) 167
Newsletter (82) 82
Newspaper Article (50) 50
Publication (45) 45
Transcript (15) 15
Conference Proceeding (7) 7
Book Chapter (4) 4
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
treprostinil (549) 549
index medicus (365) 365
pulmonary hypertension (346) 346
humans (342) 342
hypertension, pulmonary - drug therapy (259) 259
pulmonary arterial hypertension (223) 223
prostacyclin (177) 177
epoprostenol (173) 173
epoprostenol - analogs & derivatives (170) 170
female (167) 167
male (166) 166
respiratory system (164) 164
cardiac & cardiovascular systems (138) 138
therapy (132) 132
antihypertensive agents - therapeutic use (126) 126
hypertension, pulmonary - physiopathology (122) 122
pharmacology & pharmacy (122) 122
bosentan (121) 121
middle aged (119) 119
survival (119) 119
adult (118) 118
antihypertensive agents - administration & dosage (118) 118
treatment outcome (116) 116
double-blind (115) 115
epoprostenol - administration & dosage (115) 115
iloprost (101) 101
care and treatment (100) 100
epoprostenol - therapeutic use (100) 100
drug therapy (99) 99
inhaled iloprost (96) 96
sildenafil (94) 94
oral treprostinil (92) 92
5 inhibitor therapy (81) 81
hypertension (80) 80
arterial-hypertension (79) 79
research (76) 76
continuous intravenous epoprostenol (74) 74
endothelin receptor antagonist (74) 74
abridged index medicus (72) 72
aged (68) 68
efficacy (68) 68
prostacyclin analog (68) 68
antihypertensive agents - adverse effects (67) 67
epoprostenol - adverse effects (65) 65
familial primary pulmonary hypertension (60) 60
randomized controlled-trial (59) 59
drug therapy, combination (58) 58
infusion (58) 58
controlled-trial (54) 54
dosage and administration (54) 54
subcutaneous treprostinil (54) 54
intellectual property (51) 51
diagnosis (50) 50
adolescent (49) 49
pharmacokinetics (46) 46
medicine, general & internal (45) 45
combination therapy (44) 44
dose-response relationship, drug (43) 43
hypertension, pulmonary - diagnosis (43) 43
placebo-controlled trial (43) 43
safety (42) 42
health aspects (41) 41
critical care medicine (39) 39
analysis (38) 38
hypertension, pulmonary - mortality (38) 38
pharmaceutical industry (38) 38
pulmonary arteries (38) 38
administration, oral (37) 37
endothelin receptor antagonists (37) 37
mortality (37) 37
young adult (37) 37
animals (36) 36
retrospective studies (36) 36
prostanoids (35) 35
sildenafil citrate (35) 35
child (34) 34
clinical trials (34) 34
infusions, intravenous (34) 34
pulmonary/respiratory (34) 34
inhaled treprostinil (33) 33
patients (33) 33
reports (33) 33
tadalafil (33) 33
administration, inhalation (32) 32
complications and side effects (32) 32
follow-up studies (32) 32
hypertension, pulmonary - etiology (32) 32
medicine & public health (32) 32
prostaglandins (32) 32
surgery (32) 32
vasodilator agents - therapeutic use (32) 32
disease (31) 31
drugs (31) 31
intravenous epoprostenol (31) 31
management (31) 31
registry (31) 31
sulfonamides - therapeutic use (31) 31
time factors (31) 31
bosentan therapy (30) 30
endothelin (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (661) 661
Spanish (23) 23
German (5) 5
French (4) 4
Russian (4) 4
Polish (3) 3
Portuguese (3) 3
Japanese (2) 2
Czech (1) 1
Italian (1) 1
Slovak (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


La Revue de medecine interne, ISSN 0248-8663, 06/2019, Volume 40, p. A113
La maladie de Degos ou papuloseatrophiante maligne est une pathologie multi systemiquevaso-occlusive rare des petits vaisseaux, d'etiologie inconnue, decrite... 
Treprostinil
Journal Article
Chest, ISSN 0012-3692, 2016, Volume 149, Issue 5, pp. 1234 - 1244
Background In recent years, the population of patients with pulmonary arterial hypertension (PAH) has changed dramatically, including more advanced age at... 
Pulmonary/Respiratory | outcomes | pulmonary arterial hypertension | pulmonary hypertension | age | Pulmonary arterial hypertension | Age | Outcomes | Pulmonary hypertension | 5 INHIBITOR THERAPY | REGISTRIES | HEART-FAILURE | PRESERVED EJECTION FRACTION | RANDOMIZED CONTROLLED-TRIAL | TADALAFIL | ENDOTHELIN RECEPTOR ANTAGONIST | 6-MINUTE WALK | RESPIRATORY SYSTEM | ORAL TREPROSTINIL | EPIDEMIOLOGY | CRITICAL CARE MEDICINE | Multivariate Analysis | Age Factors | Vasodilator Agents - therapeutic use | Humans | Middle Aged | Pulmonary Wedge Pressure | Male | Treatment Outcome | Antihypertensive Agents - therapeutic use | Randomized Controlled Trials as Topic | Epoprostenol - therapeutic use | Epoprostenol - analogs & derivatives | Phenotype | Female | Aged | Hypertension, Pulmonary - drug therapy | Tadalafil - therapeutic use | Walk Test | Hypertension, Pulmonary - etiology | Connective Tissue Diseases - complications | Care and treatment | Prognosis | Aged patients | Research | Health aspects | Causes and theories of causation | Diseases | Index Medicus | Abridged Index Medicus | PAWP, pulmonary artery wedge pressure | FREEDOM-C2 (F-C2), Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension | S+T, SC-TRE and TRUST | TRIUMPH, Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension | ERA, endothelin receptor antagonists | Original Research | PHIRST, Pulmonary Arterial Hypertension and Response to Tadalafil | SC-TRE, Subcutaneous Infusion of Treprostinil in Patients with PAH | PVR, pulmonary vascular resistance | REVEAL, Registry to Evaluate Early and Long-term PAH Disease Management | PH, pulmonary hypertension | PAH, pulmonary arterial hypertension | WHO, World Health Organization | Pulmonary Vascular Disease | 6MWD, 6-min walk distance | or PDE-5I for the Treatment of PAH | COMPERA, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension | PDE-5I, phosphodiesterase type 5 inhibitors | TRUST, Study of Intravenous Remodulin in Patients in India with PAH | FREEDOM-M (F-M), Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension | mPAP, mean pulmonary artery pressure | CTD, connective tissue disease | FREEDOM-C (F-C), Oral Treprostinil in Combination With an ERA and
Journal Article
Journal Article
The Journal of Pediatrics, ISSN 0022-3476, 03/2019, Volume 206, pp. 305 - 306
Journal Article
Journal of Pediatrics, ISSN 0022-3476, 03/2019, Volume 206, pp. 305 - 306
Journal Article
Circulation, ISSN 0009-7322, 02/2013, Volume 127, Issue 5, pp. 624 - 633
Journal Article
Journal Article
Journal of Pharmacy Practice, ISSN 0897-1900, 10/2019, Volume 32, Issue 5, pp. 599 - 604
Treprostinil diolamine is the first oral dosage preparation of a prostacyclin analogue for use in treatment naive pulmonary arterial hypertension (PAH). This... 
prostacyclin | oral treprostinil | pulmonary hypertension | transition | switch
Journal Article
Journal Article
Journal of Heart and Lung Transplantation, ISSN 1053-2498, 2013, Volume 32, Issue 9, pp. 889 - 896
Journal Article
Journal of Heart and Lung Transplantation, ISSN 1053-2498, 07/2019, Volume 38, Issue 7, pp. 748 - 756
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 809 - 818
Journal Article
Lung, ISSN 0341-2040, 6/2018, Volume 196, Issue 3, pp. 305 - 312
Journal Article
Chest, ISSN 0012-3692, 07/2008, Volume 134, Issue 1, pp. 139 - 145
Background: Treprostinil, a long-acting prostacyclin analog, diminished the symptoms of pulmonary arterial hypertension (PAH) in controlled 12-week clinical... 
Treprostinil sodium | Prostacyclin | Bosentan | Pulmonary hypertension | Combination drug therapy
Journal Article
CLINICAL TOXICOLOGY, ISSN 1556-3650, 2017, Volume 55, Issue 7, pp. 712 - 713
Conference Proceeding
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Journal Article